Last reviewed · How we verify

Abrocitinib tablet — Competitive Intelligence Brief

Abrocitinib tablet (abrocitinib-tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor.

marketed JAK inhibitor JAK1 Live · refreshed every 30 min

Target snapshot

Abrocitinib tablet (abrocitinib-tablet) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abrocitinib tablet TARGET abrocitinib-tablet Pfizer marketed JAK inhibitor JAK1
Leqselvi DEURUXOLITINIB Sun Pharm Inds Inc marketed JAK1, JAK2, TYK2 2024-01-01
Cibinqo Abrocitinib Pfizer marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK1 2022-01-01
Cibinqo abrocitinib Pfizer marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK1 2022-01-01
ABROCITINIB ABROCITINIB marketed Janus Kinase Inhibitor [EPC] JAK1 2021-01-01
Jyseleca FILGOTINIB Gilead Sciences Ireland UC marketed Tyrosine-protein kinase JAK1 2020-01-01
Janus Kinase Inhibitor Janus Kinase Inhibitor Peking Union Medical College Hospital marketed Janus Kinase Inhibitor JAK1, JAK2, JAK3, TYK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

  1. Pfizer · 19 drugs in this class
  2. Aclaris Therapeutics, Inc. · 2 drugs in this class
  3. Beijing Friendship Hospital · 2 drugs in this class
  4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
  5. CAGE Bio Inc. · 1 drug in this class
  6. CTI BioPharma · 1 drug in this class
  7. Celgene · 1 drug in this class
  8. Fred Hutchinson Cancer Center · 1 drug in this class
  9. LEO Pharma · 1 drug in this class
  10. McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abrocitinib tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/abrocitinib-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: